A long-held dogma in neurosurgery is that parenchymal arteriovenous malformations (AVMs) are congenital. However, there is no strong evidence supporting this theory. An increasing number of documented cases of de novo formation of parenchymal AVMs cast doubt on their congenital nature and suggest that indeed the majority of these lesions may form after birth. Further evidence suggesting the postnatal development of parenchymal AVMs comes from the exceedingly rare diagnosis of these lesions in utero despite the widespread availability of high-resolution imaging modalities such as ultrasound and fetal MRI. The exact mechanism of AVM formation has yet to be elucidated, but most likely involves genetic susceptibility and environmental triggering factors. In this review, the authors report 2 cases of de novo AVM formation and analyze the evidence suggesting that they represent an acquired condition.

Case Reports

Case 1

A 35-year-old woman with a history of liver cirrhosis suffered a parenchymal bleed from a large parietooccipital AVM. High-resolution MRI done 4 years earlier, in the course of evaluation of confusion due to hepatic encephalopathy, had not shown any abnormal vascularity in the left parietooccipital area (Fig. 1).

Case 2

A 56-year-old man presenting with a transient neurological event underwent cerebral angiography. A left internal carotid artery (ICA) injection demonstrated an AVM with feeding vessels from the middle cerebral artery. An angiogram acquired 14 years earlier for evaluation of a transient ischemic attack did not show vascular malformations (Fig. 2).

Discussion

Current Paradigm

Based on observations of the normal development of the cerebral vasculature, it has been hypothesized that AVMs originate early during embryonic development in the interval when the embryo is between 40 and 80 mm in length. During this period, numerous processes such as vasculogenesis, angiogenesis, vascular remodeling, and differentiation take place, leading to a mature intracranial...
vasculature when the fetus reaches 80 mm in length. Based on this theory and on the observation that AVMs can be found in infants, it is commonly accepted that parenchymal AVMs are present at birth and follow a silent course before becoming clinically evident. This long-held theory is widely accepted even though there is little evidence that parenchymal AVMs are indeed congenital lesions.

Clinical Evidence of De Novo Formation of AVMs

A growing number of cases of de novo AVM formation are being documented, which challenges the concept of this lesion’s congenital nature. Including the patients described in the present report, we were able to find 16 cases of de novo AVMs (Table 1). All of these patients had undergone high-resolution baseline imaging that showed no evidence of vascular malformations, although only 6 of these patients were initially evaluated with catheter angiography. The indications for the initial evaluation were variable. These included vascular abnormalities (such as moyamoya disease, dural arteriovenous fistula, cavernous malformation with developmental venous anomaly, AVMs in other location, and intraparenchymal hemorrhage) and nonvascular conditions such as a brain tumor, neuronal migration abnormality, Bell’s palsy, head trauma, and demyelinating lesions. Repeat imaging leading to the diagnosis of the de novo AVM was performed after a prolonged interval, ranging from 2 to 17 years, for the purpose of following up the original lesion or due to the acute development of symptoms (which were related to AVM rupture in 3 cases). The age distribution of these patients is wide, ranging from 6 to 68 years at the time of de novo AVM diagnosis (mean 26.4 years).

Diagnosis of Intracranial Vascular Malformations in the Perinatal Period

The refinement of prenatal imaging techniques such as 3D ultrasonography and fetal MRI has improved the rate of detection of anomalies such as neural tube defects and neuronal migration and proliferation disorders. Similarly, modern color Doppler ultrasound allows a thorough evaluation of the fetal cerebrovascular circulation. However, prenatal diagnosis of a parenchymal AVM is exceedingly rare, which is in contrast to other vascular lesions (for example, vein of Galen aneurysmal malformations) that are frequently detected in utero or shortly after birth. Furthermore, the number of AVMs diagnosed in the neonatal period is also limited, and it is estimated that only 1% of AVMs are diagnosed during the first 2 years of life. These facts further bring into question the assumption that AVMs develop early during embryonic development and are present at birth.

Putative Mechanisms of AVM Formation

The congenital nature of brain AVMs has been previously questioned by others, and as we have discussed, there is compelling evidence suggesting the postnatal development of many of these lesions. However, the exact mechanism of AVM formation has yet to be elucidated, and it may involve an interaction between genetic susceptibility and environmental (acquired) factors. Several studies of patients with hereditary hemorrhagic telangiectasia (HHT), an autosomal dominant disease that includes AVMs in multiple sites (brain included) as part of its clinical spectrum, have improved our understanding of these vascular lesions. Loss-of-function mutations have been identified in the 2 main subtypes of the disease. Specifically, the gene coding for endoglin (ENG) is altered in patients with HHT Type 1 and the gene coding for activin-like kinase 1 (ALK1) is mutated in patients with HHT Type 2. Both ENG and ALK1 are proteins involved in signaling pathways of the transforming growth factor–β, critical for angiogenesis and inflammation.

A possible genetic influence in the formation of AVMs outside the setting of HHT is suggested by various reports of familial clustering of sporadic AVMs. In addition, a variety of candidate gene studies in patients...
Are parenchymal AVMs congenital lesions?

with sporadic AVMs have identified single-nucleotide polymorphisms (SNPs) associated with a susceptibility to develop AVMs and with their progression to intracerebral hemorrhage.\textsuperscript{20,34} Most of the studied genes code for essential proteins in the angiogenic and inflammatory cascades. A recent systematic review included all the studies reporting SNPs associated with sporadic brain AVMs, and after a joint analysis of the risk estimates described in the different reports, a statistically significant association was found between an SNP in the \textit{ALK1} gene (intervening sequence 3′–35A>G) and a susceptibility to develop a brain AVM (OR 2.19, 95% CI 1.25–3.83).\textsuperscript{34} A significant association was also found between SNPs in genes coding for interleukin 6 and tumor necrosis factor–\alpha and risk of intracranial hemorrhage.\textsuperscript{34}

Genome-wide association studies can potentially disclose novel genetic loci influencing AVM formation.\textsuperscript{34} The first of such studies in patients with sporadic brain AVMs examined the association of common and rare copy number variations (CNVs) and disease susceptibility in 371 patients with sporadic brain AVMs and 563 controls.\textsuperscript{6} A CNV was identified on initial screening but did not replicate in an independent cohort of patients.\textsuperscript{6} Similarly, no association was found between rare CNVs and disease susceptibility.\textsuperscript{6} However, larger, well-powered studies might be able to detect significant associations.

In addition to their genetic basis, the biology and microenvironment of AVMs is now better understood.\textsuperscript{19,20,22} Studies of AVM tissue have shown increased endothelial cell proliferation and increased expression of angiopoietin-2 and vascular endothelial growth factor, which promote vascular destabilization and proliferation, respectively.\textsuperscript{17} However, the exact triggering event that leads to increased and disorganized angiogenesis ultimately leading to AVM formation has not been identified. Mice with \textit{ALK1} deficiency develop de novo AVMs after angiogenic stimulation.\textsuperscript{8} This finding suggests that the presence of a genetic abnormality alone is not enough to trigger AVM formation and a “second hit” is required.\textsuperscript{22}

A possible mechanism to explain AVM formation may not be dissimilar to that responsible for dural arteriovenous fistulas—that is, venous thrombosis leading to impaired venous outflow, ischemia, and increased angiogenesis.\textsuperscript{1} In the case of brain AVMs, asymptomatic parenchymal venous thrombosis could trigger local venous hypertension and ischemia.\textsuperscript{1} The ischemic stimulus triggers vascular proliferation (through increased expression of hypoxia-inducible factor–1), which in normal circumstances is self-limited.\textsuperscript{12} However, in the presence of genetic susceptibility and abnormalities of the angiogenesis and inflammatory cascades, there may be uncontrolled vascular proliferation and arteriovenous shunt forma-

\begin{figure}
\centering
\includegraphics[width=\textwidth]{fig2.png}
\caption{Case 2. Initial and repeat catheter angiograms. Baseline angiograms after left ICA injection did not show any abnormalities (anteroposterior [A] and lateral [B] views). Repeat angiograms 14 years later showed an AVM with feeding vessels from the left MCA (arrows) with superficial venous drainage into the superior sagittal sinus (arrowheads) (anteroposterior [C] and lateral [D]).}
\end{figure}
TABLE 1: Reported cases of de novo formation of AVMs*

<table>
<thead>
<tr>
<th>Authors &amp; Year</th>
<th>Age (yrs)</th>
<th>Indication</th>
<th>Modality</th>
<th>Findings</th>
<th>Interval (yrs)†</th>
<th>Age (yrs)</th>
<th>Indication</th>
<th>Modality</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Schmit et al., 1996</td>
<td>8</td>
<td>11</td>
<td>MRI, angiography</td>
<td>lt frontal &amp; lt parietal infarcts, stenosis of lt MCA; compatible w/ moyamoya disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>It posterior parietal AVM</td>
</tr>
<tr>
<td>Friedman et al., 2000</td>
<td>2</td>
<td>68</td>
<td>MRI, angiography</td>
<td>tentorial DAVF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>superior cerebellar vermis AVM</td>
</tr>
<tr>
<td>Bulsara et al., 2002</td>
<td>6</td>
<td>32</td>
<td>MRI, angiography</td>
<td>demyelinating lesion in midbrain, no vascular abnormalities</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>intraparenchymal hemorrhage, rt posterior temporal AVM</td>
</tr>
<tr>
<td>Miyasaka et al., 2003</td>
<td>8</td>
<td>58</td>
<td>MRI, angiography</td>
<td>rt parietal ICH, negative angiography</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>perimesencephalic SAH; frontal, parietal, &amp; occipital AVMs</td>
</tr>
<tr>
<td>Akimoto et al., 2003</td>
<td>17</td>
<td>27</td>
<td>CT, angiography</td>
<td>IVH, 2 AVMs, splenium of corpus callosum &amp; occipital lobe</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>IVH; AVM fed by bilat pericallosal arteries</td>
</tr>
<tr>
<td>Gonzalez et al., 2005</td>
<td>3</td>
<td>6</td>
<td>MRI</td>
<td>lt frontal contusion</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>rt posterior temporal AVM</td>
</tr>
<tr>
<td>O'Shaughnessy et al., 2005</td>
<td>3</td>
<td>6</td>
<td>MRI</td>
<td>lt frontal ischemic stroke</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>AVM rt sylvian fissure</td>
</tr>
<tr>
<td>Stevens et al., 2009</td>
<td>3</td>
<td>9</td>
<td>MRI</td>
<td>band heterotopia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>lt temporooccipital AVM</td>
</tr>
<tr>
<td>Mahajan et al., 2010</td>
<td>14</td>
<td>30</td>
<td>MRI</td>
<td>no vascular abnormalities</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>lt frontoparietal AVM</td>
</tr>
<tr>
<td>Alvarez et al., 2012</td>
<td>2</td>
<td>8</td>
<td>MRI</td>
<td>rt temporooccipital giant cavernous malformation &amp; developmental venous anomaly</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>choroidal-type AVM</td>
</tr>
<tr>
<td>Mathon et al., 2013</td>
<td>4</td>
<td>9</td>
<td>MRI</td>
<td>medulloblastoma, no vascular abnormalities</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>rt temporal AVM</td>
</tr>
<tr>
<td>Fujimura et al., 2014</td>
<td>4</td>
<td>14</td>
<td>MRI</td>
<td>steno-occlusive changes, terminal portion of bilateral ICAs; compatible w/ moyamoya disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>rt occipital AVM</td>
</tr>
</tbody>
</table>

present cases
- Case 1: 31 hepatic encephalopathy MRI angiography no vascular abnormalities
- Case 2: 42 TIA MRI angiography no vascular abnormalities

* DAVF = dural arteriovenous fistula; ICH = intracerebral hemorrhage; IVH = intraventricular hemorrhage; MCA = middle cerebral artery; MRA = MR angiography; SAH = subarachnoid hemorrhage; SRS = stereotactic radiosurgery; TIA = transient ischemic attack.
† Interval between baseline imaging and diagnosis of the de novo AVM.
Are parenchymal AVMs congenital lesions?

Once high flow is established through the vascular lesion, endothelial shear stress contributes to a continued angiogenic stimulus and a hyperangiogenic environment.

Conclusions

Evidence of de novo formation of brain AVMs and a better understanding of their genetic and molecular basis challenge the traditional concept of their congenital nature and suggest that they most likely represent an acquired condition. The exact mechanism of AVM formation is not yet known but most likely involves an environmental trigger leading to increased angiogenesis in the setting of abnormalities of the genes involved in angiogenesis and inflammatory cascades and predisposing to disorganized vascular proliferation.

Disclosure

Dr. Lanzino reports being a consultant for ev3/Covidien, Edge Therapeutics, Inc., and Codman/Johnson & Johnson.

Author contributions to the study and manuscript preparation include the following. Conception and design: all authors. Acquisition of data: Lanzino, Morales-Valero, Bortolotti. Analysis and interpretation of data: all authors. Drafting the article: Lanzino, Morales-Valero. Critically revising the article: all authors. Reviewed submitted version of manuscript: all authors. Study supervision: Lanzino.

References


Manuscript submitted May 15, 2014. Accepted June 11, 2014. Please include this information when citing this paper: DOI: 10.3171/2014.6.FOCUS14234.
Address correspondence to: Giuseppe Lanzino, M.D., Department of Neurologic Surgery, Mayo Clinic, 200 SW First St., Rochester, MN 55905. email: lanzino.giuseppe@mayo.edu.